Abstract:Nanocarriers are candidates for cancer chemotherapy delivery, with growing numbers of clinically-approved nano-liposomal formulations such as Doxil® and Onivyde® (liposomal doxorubicin and irinotecan) providing proof-of-concept. However, their complex biodistribution and the varying susceptibility of individual patient tumours to nanoparticle deposition remains a clinical challenge. Here we describe the preparation, characterisation, and biological evaluation of phospholipidic structures containing solid magnetic cores (SMLs) as an MRI-trackable surrogate that could aid in the clinical development and deployment of nano-liposomal formulations. Through the sequential assembly of size-defined iron oxide nanoparticle clusters with a stabilizing anionic phospholipid inner monolayer and an outer monolayer of independently-selectable composition, SMLs can mimic physiologically a wide range of nano-liposomal carrier compositions. In patient-derived xenograft models of pancreatic adenocarcinoma, similar tumour deposition of SML and their nano-liposomal counterparts of identical bilayer composition was observed in vivo, both at the tissue level (fluorescence intensities of 1.5 × 108 ± 1.8 × 107 and 1.2 × 108 ± 6.3 × 107, respectively; ns, 99% confidence interval) and non-invasively using MR imaging. We observed superior capabilities of SML as a surrogate for nano-liposomal formulations as compared to other clinically-approved iron oxide nano-formulations (ferumoxytol). In combination with diagnostic and therapeutic imaging tools, SMLs have high clinical translational potential to predict nano-liposomal drug carrier deposition and could assist in stratifying patients into treatment regimens that promote optimal tumour deposition of nanoparticulate chemotherapy carriers. STATEMENT OF SIGNIFICANCE: Solid magnetoliposomes (SMLs) with compositions resembling that of FDA-approved agents such as Doxil® and Onivyde® offer potential application as non-invasive MRI stratification agents to assess extent of tumour deposition of nano-liposomal therapeutics prior to administration. In animals with pancreatic adenocarcinoma (PDAC), SML-PEG exhibited (i) tumour deposition comparable to liposomes of the same composition; (ii) extended circulation times, with continued tumour deposition up to 24 hours post-injection; and (iii) MRI capabilities to determine tumour deposition up to 1 week post-injection, and confirmation of patient-to-patient variation in nanoparticulate deposition in tumours. Hence SMLs with controlled formulation are a step towards non-invasive MRI stratification approaches for patients, enabled by evaluation of the extent of deposition in tumours prior to administration of nano-liposomal therapeutics.

Magnetic Mesoporous Nanospheres Anchored with LyP-1 As an Efficient Pancreatic Cancer Probe.

Targeting Pancreatic Cancer Cells with Peptide-Functionalized Polymeric Magnetic Nanoparticles

Targeting Pancreatic Cancer with Magneto-Fluorescent Theranostic Gold Nanoshells.

MR-fluorescent dual-modality molecular probes anchored with LyP-1 for pancreatic cancer

Tlyp-1-conjugated Mesoporous Silica Nanoparticles for Tumor Targeting and Penetrating Hydrophobic Drug Delivery

Optical Magnetic Multimodality Imaging of Plectin-1-Targeted Imaging Agent for the Precise Detection of Orthotopic Pancreatic Adenocarcinoma

Tlyp-1-conjugated Core-Shell Nanoparticles, Fe3O4NPs@mSiO2, for Tumor-Targeted Drug Delivery

Preparation and characterization of PLGA-based magnetic polymer nanoparticles for targeting pancreatic adenocarcinoma

A Novel Plectin/integrin-Targeted Bispecific Molecular Probe for Magnetic Resonance/near-Infrared Imaging of Pancreatic Cancer.

Development of Peptide Conjugated Superparamagnetic Iron Oxide (SPIO) Nanoparticles for Targeted MR Imaging and Therapy of Pancreatic Cancer

MUC‐1 aptamer targeted superparamagnetic iron oxide nanoparticles for magnetic resonance imaging of pancreatic cancer in vivo and in vitro experiment

Molecular Mechanism of Pancreatic Tumor Metastasis Inhibition by Gd@C82(OH)22 and Its Implication for De Novo Design of Nanomedicine.

Biocompatibility, MR imaging and targeted drug delivery of a rattle-type magnetic mesoporous silica nanosphere system conjugated with PEG and cancer-cell-specific ligands

Metformin-Induced Stromal Depletion to Enhance the Penetration of Gemcitabine-Loaded Magnetic Nanoparticles for Pancreatic Cancer Targeted Therapy

Optical Magnetic Multimodality Imaging of Plectin-1-targeted Imaging Agent for the Precise Detection of Orthotopic Pancreatic Ductal Adenocarcinoma in Mice.

Actively-targeted LTVSPWY Peptide-Modified Magnetic Nanoparticles for Tumor Imaging

Molecular Imaging of Pancreatic Cancer in an Animal Model Using Targeted Multifunctional Nanoparticles.

Hollow Manganese Phosphate Nanoparticles As Smart Multifunctional Probes for Cancer Cell Targeted Magnetic Resonance Imaging and Drug Delivery

Synthesis and functionalization of protease-activated nanoparticles with tissue plasminogen activator peptides as targeting moiety and diagnostic tool for pancreatic cancer

Surface Engineered Antifouling Optomagnetic SPIONs for Bimodal Targeted Imaging of Pancreatic Cancer Cells

Long-circulating magnetoliposomes as surrogates for assessing pancreatic tumour permeability and nanoparticle deposition